Want to see JP:4483 full AI Analyst Report?
Top Page
JMDC Inc.
(4483)
Select Model
Select Model
Rating:63Neutral
Price Target:
¥3,962.00
▼(-15.65% Downside)
Action:Downgraded
Date:08/09/26
The score is driven primarily by solid financial performance (profitable growth with positive recent free cash flow), tempered by balance-sheet and cash-flow volatility risks. Technicals are moderately supportive in the near term but constrained by a weak longer-term trend (below the 200-day average). Valuation is the main drag due to a high P/E and low dividend yield.
Positive Factors
Strong multi-year revenue growth
Strong multi-year revenue compounding indicates sustained demand for JMDC’s healthcare data and analytics services. Continued expansion can deepen customer adoption, increase the value of its structured datasets, and provide a durable base for earnings growth over the next several quarters.
Negative Factors
Rising leverage
Increasing leverage reduces financial flexibility even though debt remains below equity in the latest periods. A higher debt burden can limit JMDC’s ability to absorb weaker growth or fund new investments internally, while also making future capital allocation more sensitive to financing costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong multi-year revenue growth
Strong multi-year revenue compounding indicates sustained demand for JMDC’s healthcare data and analytics services. Continued expansion can deepen customer adoption, increase the value of its structured datasets, and provide a durable base for earnings growth over the next several quarters.
Read all positive factors
JMDC Inc. (4483) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥243.46B
Dividend Yield0.48%
Average Volume (3M)254.48K
Price to Earnings (P/E)35.5
Beta (1Y)0.86
Revenue Growth18.89%
EPS Growth11.66%
CountryJP
Employees2,444
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)105.92
Shares Outstanding65,447,205
10 Day Avg. Volume197,880
30 Day Avg. Volume254,480
Financial Highlights & Ratios
PEG Ratio2.34
Price to Book (P/B)2.53
Price to Sales (P/S)4.20
P/FCF Ratio26.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥4,374.29Price Target Upside-6.87% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)114.78
Revenue Forecast (FY)¥60.40B
JMDC Inc. Business Overview & Revenue Model
Company Description
JMDC Inc. is a Japanese corporation primarily focused on delivering analytical and statistical services for the medical sector. Its operations are structured across three principal divisions: Healthcare-Big Data, Telemedicine, and Dispensing Pharm...
How the Company Makes Money
JMDC makes money primarily by monetizing healthcare data through data-driven services delivered to enterprise customers. Key revenue streams typically include: (1) data platform and analytics services sold to life sciences companies, where JMDC pr...
JMDC Inc. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
66
Positive
Cash Flow
61
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 52.34B | 50.46B | 41.72B | 30.57B | 27.81B | 21.81B |
| Gross Profit | 28.93B | 27.69B | 22.47B | 17.10B | 14.77B | 11.63B |
| EBITDA | 14.18B | 13.81B | 11.43B | 7.57B | 7.98B | 6.51B |
| Net Income | 6.93B | 6.76B | 5.96B | 3.32B | 4.27B | 3.25B |
Balance Sheet | ||||||
| Total Assets | 154.06B | 158.54B | 143.02B | 122.45B | 98.57B | 62.05B |
| Cash, Cash Equivalents and Short-Term Investments | 30.78B | 28.95B | 32.18B | 14.47B | 22.78B | 13.19B |
| Total Debt | 51.03B | 52.05B | 46.89B | 37.83B | 20.40B | 17.80B |
| Total Liabilities | 70.85B | 74.35B | 64.54B | 51.76B | 34.04B | 30.89B |
| Stockholders Equity | 83.06B | 83.68B | 78.02B | 70.59B | 64.54B | 31.17B |
Cash Flow | ||||||
| Free Cash Flow | 8.72B | 8.01B | 12.57B | -910.00M | 3.24B | 3.36B |
| Operating Cash Flow | 9.44B | 8.59B | 14.69B | -17.00M | 4.06B | 3.81B |
| Investing Cash Flow | -6.39B | -10.56B | -3.47B | -24.86B | -22.77B | -8.10B |
| Financing Cash Flow | -7.91B | -1.26B | 6.48B | 16.58B | 28.30B | -2.41B |
JMDC Inc. Technical Analysis
Positive
4697.00
Price Trends
3470.50
Positive
3182.84
Positive
3373.53
Positive
Market Momentum
64.24
Negative
58.65
Neutral
67.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4483, the sentiment is Positive. The current price of 4697 is above the 20-day moving average (MA) of 3611.00, above the 50-day MA of 3470.50, and above the 200-day MA of 3373.53, indicating a bullish trend. The MACD of 64.24 indicates Negative momentum. The RSI at 58.65 is Neutral, neither overbought nor oversold. The STOCH value of 67.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4483.
JMDC Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥1.26T | 27.77 | 11.45% | 1.19% | 15.76% | 13.53% | |
73 Outperform | ¥31.93B | 9.18 | ― | 3.38% | 4.90% | 60.31% | |
63 Neutral | ¥243.46B | 35.50 | ― | 0.48% | 18.89% | 11.66% | |
59 Neutral | ¥77.29B | 40.15 | 12.35% | 0.00% | 24.03% | 34.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥2.49B | -5.17 | ― | ― | 14.84% | 30.67% |
* Healthcare Sector Average
JP:4483
JMDC Inc.
3,720.00
-973.17
-20.74%
JP:2413
M3
1,856.00
-407.86
-18.02%
JP:4480
Medley
2,430.00
72.00
3.05%
JP:4438
Welby Inc.
292.00
-6.00
-2.01%
JP:9438
MTI Ltd.
592.00
-160.70
-21.35%
JMDC Inc. Corporate Events
JMDC Lifts Full-Year Earnings Outlook on Strong First-Quarter Growth
Aug 5, 2026
JMDC Inc. reported consolidated revenue of ¥12.605 billion for the three months ended June 30, 2026, a 17.5% year-on-year increase, with operating profit rising 17.5% to ¥1.823 billion. Profit attributable to owners of the parent grew 17...
JMDC Finalizes Terms for New Stock Option Grants to Directors and Employees
Jul 16, 2026
JMDC Inc. has finalized the terms for its 19th, 20th and 21st share subscription rights programs, approving stock options for directors, executive officers and employees of the company and its subsidiaries. The 19th program will allocate 6,540 rig...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.